Insider Selling: Neuronetics, Inc. (NASDAQ:STIM) CEO Sells 40,992 Shares of Stock

Neuronetics, Inc. (NASDAQ:STIM) CEO Keith J. Sullivan sold 40,992 shares of Neuronetics stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $3.28, for a total transaction of $134,453.76. Following the transaction, the chief executive officer now directly owns 1,283,362 shares in the company, valued at $4,209,427.36. The trade was a 3.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Neuronetics Trading Up 1.0 %

STIM traded up $0.04 during mid-day trading on Wednesday, hitting $3.97. The stock had a trading volume of 867,076 shares, compared to its average volume of 1,610,051. The firm has a market capitalization of $120.49 million, a price-to-earnings ratio of -3.23 and a beta of 2.17. Neuronetics, Inc. has a 1-year low of $0.52 and a 1-year high of $5.07. The company has a debt-to-equity ratio of 4.90, a current ratio of 3.16 and a quick ratio of 2.87. The stock’s fifty day simple moving average is $2.03 and its 200-day simple moving average is $1.36.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Tradewinds LLC. bought a new stake in shares of Neuronetics during the fourth quarter worth $32,000. Landscape Capital Management L.L.C. acquired a new position in Neuronetics in the 3rd quarter worth $53,000. GSA Capital Partners LLP increased its holdings in Neuronetics by 64.5% during the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after purchasing an additional 30,837 shares in the last quarter. David J Yvars Group raised its stake in shares of Neuronetics by 47.1% in the 4th quarter. David J Yvars Group now owns 46,325 shares of the company’s stock valued at $75,000 after purchasing an additional 14,825 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock valued at $88,000 after purchasing an additional 54,442 shares during the period. 53.59% of the stock is owned by institutional investors and hedge funds.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.